Today’s guest is Gerard Quinn, VP of Innovation & Informatics at ICON plc. Since their foundation in Dublin in 1990, ICON's mission has been to help their clients to accelerate the development of drugs and devices that save lives and improve quality of life. They do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. ICON are nominated in the Best Application of AI in a Large Enterprise category at the 2023 AI Awards for their Cassandra platform. Cassandra employs powerful machine learning models to predict FDA and EMA post-marketing requirements (PMRs) with 99% and 97% accuracy, helping pharmaceutical companies plan clinical trials effectively and reduce risks. Topics include: An overview of ICON's work serving pharmaceutical and biotech firms How the Cassandra product uses AI to AI forecast post-trial needs, assisting planning and drug access Predicting post-trial needs, aiding proactive planning, avoiding delays and costs AI built with data sourcing for trial design and business use AI's limitless potential in clinical research for automation and problem-solving

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.